Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine. Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.
Following the announcement in June of a new philanthropic relationship between Bvlgari and the University of Oxford, Bvlgari\u2019s donation in support of DPhil students in vaccine research benefits two exceptional students, appointed as the first cohort of Bvlgari Scholars. The Jenner Institute welcomes students Cameron Bissett and Rebecca Makinson this month for the start of their DPhil courses, after demonstrating remarkable academic potential and merit in the field of vaccine-related immunology.
Thousands of lives could be saved by measuring the strength of the antibody response in those who have had the virus and how long their immunity may last for. Professor Paul Klenerman and his team at the University of Oxford have partnered with Oxford University Hospitals NHS Foundation Trust (OUH) to test thousands of healthcare workers.
Prof Chris Holmes, The Alan Turing Institute\u2019s Programme Director of Health and Medical Science, and Professor of Biostatistics at the Nuffield Department of Medicine, said: \u201cThe Turing is delighted to be playing a pivotal role in supporting the JBC by working to build an alliance with the RSS and academic experts to provide new insights in the evolving fight against COVID-19. In doing so, we will strengthen knowledge across the wider public health ecosystem.\"
New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as \u2018immunoassays\u2019), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
Scientists from the University of Oxford\u2019s Nuffield Department of Medicine have today published their evaluation of LamPORE, a novel diagnostic platform for detecting SARS-CoV-2 RNA. It combines loop-mediated isothermal amplification with nanopore sequencing. This technology has the potential to analyse thousands of samples per day on a single instrument.
A team of mathematical modellers and epidemiologists at Oxford University\u2019s Nuffield Department of Medicine release the latest model of a population responding to the coronavirus epidemic. The model - OpenABM-Covid19 - provides public health decision-makers with the ability to review the potential progression and outcome of the coronavirus, including fluctuations in infected individuals, hospitalisations, intensive care unit (ICU) admissions and deaths, and assess the impact of test and trace programmes.
Oxford University researchers have found that infection with COVID-19 produces a robust T cell response, including inducing T cell \u2018memory\u2019 to potentially fight future infections.
The latest research findings from a team of modellers and epidemiologists at Oxford University\u2019s Nuffield Department of Medicine and Google Research suggest digital contact tracing, such as that based on Google and Apple\u2019s Exposure Notification System (ENS), can help to control the epidemic at low levels of app uptake.
The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
The Phase 1 data shows that the vaccine raised no safety concerns, did not lead to any unexpected symptoms in those who received it, and was very similar to other vaccines of this type.
A generous gift of \u00a33.5 million from Lakshmi Mittal and his family has secured the future of a critical professorship in vaccinology at the University. The post, which is currently held by Professor Adrian Hill, will be known as the Lakshmi Mittal and Family Professorship of Vaccinology in recognition of this support.
Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin America\u2019s first phase 3 COVID-19 clinical trial. The trial officially began on Saturday 20th June and will enrol 5,000 volunteers across the country. Vaccinations will take place in Sao Paulo, Rio de Janeiro and a site in the Northeast of Brazil. The Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials on 2nd June, which are being conducted in partnership with AstraZeneca.
The Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group\u2019s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford\u2019s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
University of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers. The phase I trial in healthy adult volunteers began in April. More than 1,000 immunisations have been completed and follow-up is currently ongoing. The next study will enrol up to 10,260 adults and children and will involve a number of partner institutions across the country.
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford\u2019s vaccine widely accessible around the world in an equitable manner. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University. The vaccine candidate was developed by the University\u2019s Jenner Institute who began trials in humans last week jointly with the University\u2019s Oxford Vaccine Group.
Ecolab supports cleanroom environments for the University of Oxford\u2019s Clinical BioManufacturing Facility COVID-19 vaccine development and manufacture
![\"\"](\"https://www.cbf.ox.ac.uk/news/trials-of-oxford-coronavirus-vaccine-begin-in-kenya/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n